Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00693849
Registration number
NCT00693849
Ethics application status
Date submitted
6/06/2008
Date registered
9/06/2008
Date last updated
11/07/2018
Titles & IDs
Public title
International Study to Predict Optimised Treatment - in Depression
Query!
Scientific title
International Study to Predict Optimised Treatment - in Depression
Query!
Secondary ID [1]
0
0
iSPOT-D
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
iSPOT-D
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Escitalopram
Treatment: Drugs - Sertraline
Treatment: Drugs - Venlafaxine-XR
Active Comparator: A - Escitalopram
Active Comparator: B - Sertraline
Active Comparator: C - Venlafaxine-XR
No Intervention: D - Healthy matched controls
Treatment: Drugs: Escitalopram
10 mg/day as a single dose, increased to max 20 mg/day
Treatment: Drugs: Sertraline
50 mg/day as a single dose, increased to max of 200 mg/day
Treatment: Drugs: Venlafaxine-XR
75 mg/day given once daily; increased to 150-225 mg/day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDD
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 8
Query!
Secondary outcome [1]
0
0
To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
52-weeks
Query!
Eligibility
Key inclusion criteria
- Meet DSM-IV criteria for primary diagnosis of MDD.
- HAM-D17 score of = 16.
- 18-65 years age-range
- Subjects with English or Dutch literacy and fluency.
- Written, informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Presence of suicidal ideations and/or tendencies (as determined by a score >12 on
Section C, Suicidality, of the MINI Plus), Bipolar I-III, psychosis, primary eating
disorders, Post Traumatic Stress Disorder (PTSD), Obsessive Compulsive Disorder (OCD),
Post-Natal Depression as well as any Axis II personality disorders as diagnosed using
the MINI Plus or by a health care professional.
- Pregnancy and women of child bearing potential who are not taking a medically accepted
form of contraception and are at risk of becoming pregnant during the study.
- Breastfeeding.
- Known contra-indication or intolerance to the use of Escitalopram, Sertraline or
Venlafaxine XR as defined in the product package insert for each drug (including
previous treatment failure at the highest recommended dose).
- Use of any psychological or counselling therapy or antidepressant/CNS drug which
cannot be washed out prior to participation and eliminated until after Week 8 or
discontinuation.
- Use of any medication which is known to be contraindicated with Escitalopram,
Sertraline, or Venlafaxine XR (refer to the product package insert for each drug).
- Known medical condition, disease or neurological disorder which might, in the opinion
of investigator/s, interfere with the assessments to be made in the study or put
subjects at increased risk when exposed to optimal doses of the drug treatment.
- History of head injury with loss of consciousness for at least 10 minutes.
- Recent/current substance dependence (as defined in Section K of the Mini Plus as per a
6 months period and/or alcoholism) in the past six months.
- Participation in an investigational study within four months of the baseline visit in
which subjects have received an experimental drug/device that could affect the primary
end points of this study.
- Subjects who, in the opinion of the investigator, have a severe impediment to vision,
hearing and/or hand movement, which is likely to interfere with their ability to
complete the test batteries.
- Subjects who, in the opinion of the investigator, are unable and/or unlikely to
comprehend and follow the study procedures and instructions.
Query!
Study design
Purpose of the study
Health Services Research
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2019
Query!
Actual
Query!
Sample size
Target
2688
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Brain Dynamics Centre - Westmead
Query!
Recruitment hospital [2]
0
0
Flinders University - Adelaide
Query!
Recruitment hospital [3]
0
0
Swinburne University - Melbourne
Query!
Recruitment hospital [4]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
5042 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3122 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3181 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Missouri
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New Jersey
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Rhode Island
Query!
Country [9]
0
0
Netherlands
Query!
State/province [9]
0
0
Gelderland
Query!
Country [10]
0
0
New Zealand
Query!
State/province [10]
0
0
Auckland
Query!
Country [11]
0
0
South Africa
Query!
State/province [11]
0
0
Guatang
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
BRC Operations Pty. Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive)
markers (or combinations of them) that predict specific response to a range of
antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with
major depressive disorder. This study is focused on outcomes which may impact on how
"personalised medicine" is implemented in depression.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00693849
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Anthony Harris, MD
Query!
Address
0
0
Brain Dynamics Centre
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00693849
Download to PDF